A5080405709- Microscopic Colitis
- Inflammatory Bowel Disease
- Gastrointestinal motility and disorders
- Helicobacter pylori-related gastroenterology studies
- Pharmaceutical studies and practices
- Immunodeficiency and Autoimmune Disorders
- Celiac Disease Research and Management
- Iron Metabolism and Disorders
- Autoimmune and Inflammatory Disorders Research
- Trace Elements in Health
- Chronic Kidney Disease and Diabetes
- Renal Diseases and Glomerulopathies
- Childhood Cancer Survivors' Quality of Life
- Hemoglobinopathies and Related Disorders
- Potassium and Related Disorders
- Diabetes Treatment and Management
- Dialysis and Renal Disease Management
- Adolescent and Pediatric Healthcare
Maastricht University
2023-2025
Zuyderland Medisch Centrum
2022
Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk cardiovascular morbidity mortality in a wide range patients. However, their effects on some patients with are unclear because few clinical outcomes occurred among such completed trials. In particular, guidelines stratify level recommendation about who should be treated SGLT2 based diabetes status albuminuria. We aimed to assess empagliflozin both overall specific types participants...
Abstract Background Subjective patient experiences related to treatment are frequently underreported by healthcare providers, leading potential discrepancies between patients and physicians in defining remission. This can influence expectations, engagement behaviours, ultimately clinical outcomes. Based on these findings, the approach for IBD has evolved, with STRIDE-II consortium incorporating disease control from perspective into long-term goals established STRIDE-I. study aims compare...
Efficacy of infliximab in children with inflammatory bowel disease can be enhanced when serum concentrations are measured and further dosing is adjusted to achieve maintain a target concentration. Use population pharmacokinetic model may help predict an individual's dose requirement. The aim this study was evaluate the predictive performance available models independent cohort Dutch disease.
To determine whether intravenous (IV) or oral iron suppletion is superior in improving physical fitness anemic children with inflammatory bowel disease (IBD).We conducted a clinical trial at 11 centers. Children aged 8-18 IBD and anemia (defined as hemoglobin [Hb] z-score < -2) were randomly assigned to single IV dose of ferric carboxymaltose 12 weeks ferrous fumarate. Primary end point was the change 6-minute walking distance (6MWD) from baseline, expressed z-score. Secondary outcome Hb...
Fatigue is a common symptom in children with inflammatory bowel disease (IBD). Diagnostic tests to evaluate biological causes of fatigue commonly include markers inflammation and hemoglobin (Hb), yet functional parameters have been inadequately studied pediatric IBD. In this study, we compared fatigued non-fatigued IBD from both point view.A cross-sectional study 104 patients mild moderately active was conducted. Fatigued were defined as those Pediatric Quality Life Inventory...
Background: Exposure–response studies have shown that higher infliximab concentrations are associated with better outcomes in inflammatory bowel disease. There is little agreement about the optimal time to measure levels children. Objectives: We aimed evaluate whether trough at week 6 or 14 predict sustained remission. The secondary aim was define target weeks and 14. Design: used routinely collected electronic healthcare data of 70 anti-tumour necrosis factor naïve children disease treated...
Abstract Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative proposes therapeutic targets for inflammatory bowel disease (IBD) to be used a treat-to-target clinical management strategy. However, there is lack of information regarding how many patients actually achieve defined treatment as outlined STRIDE-II after initiation new therapies. objective this study was investigate the response Crohn’s (CD) according recommendations first year starting...
Abstract Background Therapeutic drug monitoring (TDM) is an approach to improve treatment effectiveness of anti-TNF therapy in Inflammatory Bowel Disease (IBD), but timing and threshold trough levels (TL) are still subject investigation, especially paediatric populations. The aims our study were (1) analyse induction – post-induction infliximab TLs (respectively after 6 14 weeks) predict sustained biochemical clinical remission between 12 months patients with IBD, (2) define at these...